The Second Lock: Santa Ana Bio’s Bet on a More Selective Immune Drug

A mast cell has an address problem. The immune cell helps set off allergic reactions, and a receptor called KIT sits on its surface. A drug can find KIT. So far, so straightforward. But KIT is found on other cells too, including cells involved in making blood and pigmentation. Hitting the right target, it turns out, is not always the same as finding the right cell. Santa Ana Bio has built its first clinical candidate around that distinction.

The Alameda company’s answer is SAB01, an antibody made to engage both KIT and a second receptor, Siglec-6. Santa Ana says that pair is co-expressed on mast cells, giving the molecule a more exact cellular address. In September 2026, the company reported that the first cohort had been dosed in a Phase 1 study. For a biotech founded in 2022 and unveiled with $168 million in financing two years later, this is the first encounter between its design and a human body.

One cell, two clues

In immunology, the usual temptation is to name a target and then make a molecule that binds it tightly. Santa Ana’s premise is slightly more demanding: first map the cells implicated in disease, then look for a combination of markers that better identifies them. The company describes a multi-omics approach that brings genomic, transcriptomic and proteomic data into the same search. Those maps inform its antibody engineering, which is where SAB01’s two-part address comes from.

There is a commercial reason to bother. KIT-directed therapies have already given the field evidence that mast cells matter in chronic hives. Celldex’s barzolvolimab, a KIT-targeting antibody, reported positive Phase 3 results in chronic spontaneous urticaria in September 2026. Santa Ana is entering a real contest, with a candidate much earlier in development. Its proposed advantage is selectivity: if two receptors must be engaged together, cells bearing KIT alone might be less affected. That is a hypothesis the company will have to establish in people, not a clinical advantage it can yet claim.

“SAB01 was designed to uncouple mast cell depletion from broad KIT inhibition.”Peter Emtage, founder and CEO

Emtage came to Santa Ana after leading cell therapy research at Kite Pharma and serving as chief scientific officer of Cell Design Labs. The company also lists four scientific founders: Alexander Rudensky, Richard Flavell, Graham Lord and Ansuman Satpathy. Their specialties range across immune regulation, inflammation and genomic profiling. This is useful expertise for a firm betting that the next drug target may be a pattern across cells rather than a single famous molecule.

A trial is a question, not a victory lap

The registered SAB01 study is randomized, double-blind and placebo-controlled. Its participants are healthy adults. It examines single ascending doses delivered under the skin or by intravenous infusion, with safety, tolerability, pharmacokinetics and pharmacodynamics among its measures. The initial plan described by Santa Ana has seven cohorts of eight people, with six assigned to SAB01 and two to placebo in each cohort. The registry allows optional cohorts, up to 88 participants in all.

That study can tell researchers whether the antibody behaves as intended at the doses tested and whether any concerning effects appear. It cannot yet show that a person with chronic hives, atopic dermatitis or food allergy will feel better. Nor can it settle whether SAB01 is safer than another drug: that would require clinical evidence fit for the comparison. Santa Ana’s site points to Phase 1 data in 2027 as the next public milestone.

The calendar deserves a line of its own. At its June 2024 debut, Santa Ana said multiple biologics were tracking toward clinical entry in 2025. The first reported SAB01 dosing arrived in September 2026. Public updates do not explain every month of that gap, so it would be foolish to invent a lab drama. It does, however, give the reader a useful measure: the journey from a persuasive molecular design to a first human dose is long even when a company starts with money, experienced executives and a clear target.

The $168 million question

Santa Ana emerged from stealth with a $43 million Series A led by founding investor Versant Ventures and a $125 million Series B led by GV. TPG’s Life Science Innovations fund joined the first round; Access Biotechnology, a16z Bio + Health and RTW joined the second alongside existing investors. Those are disclosed financing figures, not a price tag for SAB01 alone. They bought the company the ability to pursue several molecules, build a team and get the lead one into the clinic. There is no public valuation or verified commercial revenue to turn that investment into a simple return calculation.

The spending is aimed at future patients, not present customers. Santa Ana has no approved drug to sell. If its candidates eventually make it through trials and regulators, the buyers and decision makers would include health systems, clinicians and payers, while patients would use the medicines. A licensing or development partnership is also possible; Versant publicly mentioned that option at launch. There is no announced product partnership to put in the ledger today. The Phase 1 registry does list Altasciences as a clinical collaborator.

The company has broadened its management for the clinical phase. Newman Yeilding, previously a senior immunology development executive at Janssen, became chief medical officer in February 2026. Mike Bonney, formerly chief executive of Cubist Pharmaceuticals, became board chair in November 2025. Santa Ana’s careers page states values such as integrity, accountability, teamwork and respect; employees quoted there describe cross-disciplinary discussion and room to develop. Those are self-descriptions, but they fit a company whose work crosses cell biology, protein engineering and trials.

One principle, several medicines

SAB01 is the cleanest illustration of the company’s strategy, but it is not the whole pipeline. SAB05 combines a CD40-targeting antibody with a glucocorticoid payload. The idea is to bring the anti-inflammatory power of a steroid to tissue associated with CD40 activity while limiting systemic exposure. It is still in IND-enabling development. SAB06 is a portfolio of multispecific antibodies designed around pathways involved in inflammatory bowel and other gastrointestinal diseases, including TL1A and IL-23. These are preclinical programs, with 2027 IND submissions listed as goals on the company’s site.

The products differ, yet the house style is recognizable: find a more precise way to control an immune mechanism that existing medicines already suggest is important. It is a sensible recipe to borrow in research: use rich cell data to identify a more specific address, build a molecule that reads it, and choose an early experiment that could disprove the mechanism. It works only if the paired markers really distinguish the harmful cells, the drug reaches them at a useful dose, and the added engineering improves the balance of benefit and harm. A lovely diagram is no substitute for any of those conditions.

For now, Santa Ana occupies a narrow but interesting place in the immune-drug market. It is a clinical-stage challenger to established symptom treatments and much more advanced KIT programs, while also exploring targeted steroid delivery and gastrointestinal antibodies. The company has done the first hard thing: moved an idea into a human study. The next hard thing is to find out whether the second lock opens a better treatment.